Exploring the therapeutic potential of xanthine oxidase inhibitor allopurinol in angina
| ISRCTN | ISRCTN15253766 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN15253766 |
| Secondary identifying numbers | JUS002 |
- Submission date
- 21/02/2006
- Registration date
- 29/03/2006
- Last edited
- 08/11/2011
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Narasimharajapura Rajendra
Scientific
Scientific
Dept of Clinical Pharmacology
Level 7
Ninewells Hospital
Dundee
DD1 9SY
United Kingdom
| Phone | +44 (0)1382 496355 |
|---|
Study information
| Study design | Randomised double blind placebo-controlled crossover trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Not specified |
| Study type | Treatment |
| Scientific title | |
| Study objectives | Xanthine oxidase inhibition in chronic stable angina improves endothelial function. |
| Ethics approval(s) | Approved by the Regional Ethics Committee on 08/11/2005, reference number: 05/S1401/101 |
| Health condition(s) or problem(s) studied | Chronic stable angina |
| Intervention | Allopurinol versus placebo |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Allopurinol |
| Primary outcome measure | Change in endothelial function as assessed by: 1. Flow-mediated dilatation 2. Forearm venous occlusion plethysmography |
| Secondary outcome measures | Changes in brain natriuretic peptide (BNP) |
| Overall study start date | 05/01/2006 |
| Completion date | 02/04/2008 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | 88 |
| Key inclusion criteria | 1. Documented coronary artery disease 2. Chronic stable angina |
| Key exclusion criteria | 1. Left ventricular systolic dysfunction 2. Renal failure 3. Concomitant warfarin therapy 4. Allergy to allopurinol |
| Date of first enrolment | 05/01/2006 |
| Date of final enrolment | 02/04/2008 |
Locations
Countries of recruitment
- Scotland
- United Kingdom
Study participating centre
Dept of Clinical Pharmacology
Dundee
DD1 9SY
United Kingdom
DD1 9SY
United Kingdom
Sponsor information
University of Dundee (UK)
University/education
University/education
The Nethergate
University of Dundee
Dundee
DD1 4HN
Scotland
United Kingdom
"ROR" |
https://ror.org/03h2bxq36 |
|---|
Funders
Funder type
Charity
The British Heart Foundation (UK)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 16/08/2011 | Yes | No |
